VEA
SGMO

Virtus ETF Advisers’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Virtus ETF Advisers’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-29,327
Closed -$51.6K – 478
2023
Q1 		$51.6K Sell
29,327
-11,273
-28% -$32.2K 0.03% 429
2022
Q4 		$127K Buy
40,600
+8,949
+28% +$34.7K 0.07% 396
2022
Q3 		$155K Buy
31,651
+227
+0.7% +$1.17K 0.06% 348
2022
Q2 		$130K Buy
31,424
+10,441
+50% +$45.2K 0.05% 352
2022
Q1 		$122K Sell
20,983
-1,244
-6% -$7.4K 0.05% 267
2021
Q4 		$167K Buy
22,227
+4,141
+23% +$36K 0.06% 301
2021
Q3 		$163K Sell
18,086
-951
-5% -$9.4K 0.07% 320
2021
Q2 		$228K Sell
19,037
-3,913
-17% -$44.3K 0.09% 250
2021
Q1 		$288K Buy
22,950
+396
+2% +$5.34K 0.12% 248
2020
Q4 		$352K Sell
22,554
-5,495
-20% -$64.4K 0.15% 168
2020
Q3 		$265K Sell
28,049
-3,815
-12% -$41.3K 0.14% 250
2020
Q2 		$286K Sell
31,864
-10,390
-25% -$96.4K 0.14% 307
2020
Q1 		$269K Sell
42,254
-6,154
-13% -$45.7K 0.11% 241
2019
Q4 		$405K Buy
48,408
+21,277
+78% +$196K 0.07% 250
2019
Q3 		$246K Sell
27,131
-1,512
-5% -$17K 0.05% 215
2019
Q2 		$308K Buy
+28,643
New +$305K 0.06% 204
2019
Q1 		– Sell
-26,120
Closed -$300K – 250
2018
Q4 		$300K Sell
26,120
-4,015
-13% -$49.9K 0.05% 111
2018
Q3 		$511K Sell
30,135
-21,556
-42% -$328K 0.05% 119
2018
Q2 		$734K Buy
51,691
+5,242
+11% +$87.1K 0.65% 80
2018
Q1 		$883K Buy
46,449
+24,858
+115% +$531K 0.77% 61
2017
Q4 		$354K Sell
21,591
-22,391
-51% -$333K 0.44% 83
2017
Q3 		$660K Buy
43,982
+4,023
+10% +$44.5K 0.09% 73
2017
Q2 		$352K Buy
+39,959
New +$256K 0.05% 85
2016
Q4 		– Sell
-41,249
Closed -$191K – 187
2016
Q3 		$191K Hold
41,249
– – 0.09% 140
2016
Q2 		$239K Buy
41,249
+12,188
+42% +$77.7K 0.18% 105
2016
Q1 		$176K Sell
29,061
-1,786
-6% -$10.7K 0.24% 103
2015
Q4 		$282K Buy
+30,847
New +$238K 0.77% 44

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtus ETF Advisers's SGMO Position: Q2 2023 in Review

Virtus ETF Advisers sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2023, closing a stake of 29,327 shares — an estimated $51.6K sold.

Virtus ETF Advisers first reported a position in SGMO in Q4 2015 and held it in 27 quarters. The position peaked at $883K in Q1 2018. 152 funds tracked by Wall St. Rank hold SGMO as of Q2 2023.

  • Virtus ETF Advisers reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2023 after selling out during the quarter.
  • Virtus ETF Advisers sold 29,327 SANGAMO THERAPEUTICS INC shares in Q2 2023, an estimated $51.6K.
  • Virtus ETF Advisers first reported a position in SANGAMO THERAPEUTICS INC in Q4 2015 and held it in 27 quarters.
  • Virtus ETF Advisers's SANGAMO THERAPEUTICS INC position peaked at $883K in Q1 2018.
  • 152 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2023.

Based on Virtus ETF Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.